Lymphoma Clinical Trials

Showing 81-100 of 3,379 trials

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319

This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231. Secondary Objectives * To assess the event free and overall survival of patients treated with this therapy. * To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.

T-cell Acute Lymphoblastic LeukemiaT-cell LymphomaMixed Phenotype Acute Leukemia

St. Jude Children's Research Hospital100 participantsStarted Dec 2024

San Diego, California, United States • Tulsa, Oklahoma, United States • Memphis, Tennessee, United States

RECRUITING

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

NCT03932279

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.

Cutaneous T Cell Lymphoma

Northwestern University300 participantsStarted Jan 2019

Chicago, Illinois, United States

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Related Searches

Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study

Registry Study of Proton Radiotherapy in Lymphoma

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

DS-3201b in Participants With Lymphomas

Remote Monitoring and Symptom Management Digital Application

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment